Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224289
Status:
COMPLETED
Last Update Posted:
2012-12-10
First Post:
2005-09-16
Brief Title:
Effect of Age on Latanoprost 0005 in Patients With Glaucoma
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
Effect of Age on Efficacy and Response Time of Latanoprost 0005 in Patients With Glaucoma
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Latanoprost is a commonly used treatment for glaucoma Because of its mechanism of action it is plausible that the age of a patient using the medication may affect its efficacy and time of onset
We are going to study the effectiveness of Latanoprost in people of different ages to see if it changes based on the age of the patient
We are going to study the effectiveness of Latanoprost in people of different ages to see if it changes based on the age of the patient
Detailed Description:
Latanoprost is a topical ocular hypotensive medication with a well established safety and efficacy profile Its effect is mediated by an increase in uveoscleral outflow due to enzymatic degradation of the extracellular matrix within the ciliary muscle Since the amount of extracellular matrix within the human eye increases with age and uveoscleral outflow decreases with age it would be expected that there should be a difference in the efficacy of latanoprost in patients of different ages This has not been demonstrated in studies assessing the overall effect of latanoprost across adult age groups using multivariate analysis Camras CB et al 1996
However a difference in timing of onset of drug effect may get overlooked in clinical studies and in clinical practice as well as patients tend to be seen from two to eight weeks after initiation of treatment by which time any differences in response time may have already occurred and leveled off
To our knowledge there are no studies specifically looking at the timing of onset of drug effect of latanoprost in different age groups Because of the theoretical plausibility of this effect based on the mechanism of action of latanoprost this represents an opportunity to further elucidate the characteristics of this medication in a manner which has clinical and scientific relevance
Our aim is thus to determine if there is a difference in timing of onset of the ocular hypotensive effect of latanoprost in glaucoma patients of different age groups
However a difference in timing of onset of drug effect may get overlooked in clinical studies and in clinical practice as well as patients tend to be seen from two to eight weeks after initiation of treatment by which time any differences in response time may have already occurred and leveled off
To our knowledge there are no studies specifically looking at the timing of onset of drug effect of latanoprost in different age groups Because of the theoretical plausibility of this effect based on the mechanism of action of latanoprost this represents an opportunity to further elucidate the characteristics of this medication in a manner which has clinical and scientific relevance
Our aim is thus to determine if there is a difference in timing of onset of the ocular hypotensive effect of latanoprost in glaucoma patients of different age groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None